The Results of the Comparison between Olanzapine and One-Dose Dexamethasone and Four-Day Dexamethasone in Prevention of Chemotherapy induced Nausea and Vomiting in Patients with Pancreatic Cancer Receiving Modified FOLFIRINOX

The Preliminary Results of the Comparison between Olanzapine and One-Dose Dexamethasone and Four-Day Dexamethasone in Prevention of Chemotherapy induced Nausea and Vomiting in Patients with Pancreatic Cancer Receiving Modified FOLFIRINOX

Status

Unknown

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230307001

Enrollment

Registered

2023-03-07

Start date

2023-01-16

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with pancreatic cancer plan to receive modified FOLFIRINOX chemotherapy regimen modified FOLFIRINOX pancreatic cancer dexamethasone chemotherapy-induced nausea and vomiting Olanzapine

Interventions

antiemetic regimen with olanzapine 5 mg before chemotherapy and on day 2-4 before bedtime without dexamethasone on day 2-4. All patients received ondansetron 8 mg and dexamethasone 4 mg intravenousl

Experimental Drug,Placebo Comparator Drug

Olanzapine arm,Dexamethasone arm

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Eligible patients were 18 and 80 years old patients with Eastern Cooperative Oncology group (ECOG) performance status 0-1

Exclusion criteria

Exclusion criteria: preexisting nausea symptoms, inadequate organ function, allergy or contraindication to ondansetron, dexamethasone, olanzapine, cognitive compromise or having a history of dyskinesia, movement, CNS disorder or psychiatric disorder

Design outcomes

Primary

Measure	Time frame
complete response (CR) of vomiting (no vomiting) in the overall phase (0-120 hours) after start chemotherapy 0-120 hours after start chemotherapy rate of vomiting (no vomiting) in the overall phase	—

Secondary

Measure	Time frame
CR of nausea (no nausea) in the overall phase 0-120 hours after start chemotherapy rate of nausea (no nausea) ,incidence of hyperglycemia during 2 chemotherapy sessions incidence of hyperglycemia	—

Countries

Thailand

Contacts

Public ContactHathaipat Veerawatananan

Faculty of Medicine, Chulalongkorn University

hathaipat.vee@gmail.com6622564533

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026